Updates

Announcements

Lupuzor™ Phase III Pivotal Trial Update

Nov 4, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to provide an update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto immune disease. The pivotal Phase III trial is progressing in…
Board Change

Oct 23, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that Ajay Agrawal has stepped down as Non-Executive Director with immediate effect. Tim McCarthy, Non-Executive Chairman said: “We would like to thank Ajay for his contribution whilst at ImmuPharma. “In the short period of time as Chairman, I have become…
Tim McCarthy Appointed as Non-executive Chairman

Sep 30, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect. Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a…
Interim Results Announcement for the six months ended 30 June 2015

Sep 30, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2015 (the “Period”). Although we are pleased to report our interim results, we are saddened by the passing of our Chairman, Richard Warr, in late July. …
Richard Warr

Jul 29, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is truly saddened to announce that Richard Warr, Chairman, passed away late last week. Dimitri Dimitrou, Chief Executive Director said: “No words can truly convey the deep sadness we feel at Richard’s untimely passing away. Richard will be remembered and missed…
ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

Jul 27, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that registration with the U.S. National Institutes of Health – ClincialTrials.gov website has now gone ‘live’ confirming Lupuzor’s™ pivotal Phase III trial protocol and the current clinical commencement and completion of the study. Further details can be…
Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

Jul 25, 2015

ImmuPharma has also signed a Term Sheet with a US investor for a proposed private placement to fund the clinical trial. The initial instalment of funding consists of a convertible loan of US$2,000,000 plus additional capital of up to US$12,000,000, at the Company’s discretion, subject to certain criteria, over a two year period. Further disclosure…
Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™

Jun 25, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company is delighted to announce that Dr Sylviane Muller the key inventor of Lupuzor™ and Research Director at Centre National de la Recherche Scientifique (“CNRS”), and has received “The CNRS Medal of Innovation” for her discoveries made on the mechanism of action…
ANNUAL GENERAL MEETING: 2015

May 29, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table attached, click here. Please also refer to the ‘Notice of the 2015 Annual General Meeting’ in…
Notice of Annual General Meeting: 29 May 2015

May 7, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2014 will be posted to shareholders today. The Annual Report will be available later today, in electronic form, for download on the Company’s website www.immupharma.co.uk. The Company’s Annual…
Preliminary Results Announcement for the year ended 31 December 2014

Apr 30, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its preliminary audited results for the year ended 31 December 2014. Key Highlights: LupuzorTM Agreement signed with Simbec-Orion, an international clinical research organisation, to undertake crucial Phase III clinical trial including a commitment to reinvest a significant…
Dr Stéphane Méry Appointed as Non-Executive Director

Apr 30, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce the appointment of Dr Stéphane Méry as non-executive director. Dr Stéphane Méry has extensive experience in the Healthcare industry. He is currently CEO of Contronics Ltd, which designs and sells laboratory monitoring equipments, and until recently he…
Cancer Update: IPP-204106

Feb 11, 2015

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, provides an update on its lead Cancer programme – IPP-204106. As previously stated, the Phase I/IIa clinical trial with the next generation “polyplexed Nucant” formulation taking place in three European hospitals including the prestigious Institute Jules Bordet in Belgium, has been…
Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status

Jan 27, 2015

ImmuPharma PLC (AIM: IMM) (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has received advance assurance from H M Revenue and Customs that it would qualify for Enterprise Investment Scheme (EIS) status. EIS offers a range of tax reliefs to investors who invest in qualifying companies. These tax reliefs…
Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion

Jan 22, 2015

Deal provides powerful validation for Lupuzor™ ImmuPharma PLC (AIM: IMM) (“ImmuPharma”) and Simbec-Orion Group Limited (“Simbec-Orion”) announce that they have today entered into a Collaboration Agreement for the execution of ImmuPharma’s Pivotal Phase III clinical study of Lupuzor™. Lupuzor™ (also known as Rigerimod, IPP-201101 and P140), is ImmuPharma’s lead compound for the treatment of Lupus,…
ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France

Oct 21, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is proud to announce that the French region of Aquitaine (around Bordeaux) has awarded ImmuPharma’s subsidiary Ureka a non-refundable grant of approx. €400,000 EUR to develop Ureka’s Urelix technology. The Urelix technology is a way to mimic natural peptides having a…
AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress

Oct 21, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, announces that it has conditionally, raised approximately £3.4 million. This is principally from ImmuPharma’s long standing shareholder Aviva Investors through a placing of 6,340,000 new ordinary shares of 10p each in the Company, at a price of 53 pence per share,…
INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014

Oct 2, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2014. KEY HIGHLIGHTS • LupuzorTM – Announced separately today – Phase III activities of lead compound Lupuzor™ will soon commence: Following advanced discussions and after completing detailed due diligence…
Lupuzor™ Gears Up To Start Pivotal Phase III trials

Oct 2, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to announce that Phase III activities of its lead compound Lupuzor™ will soon commence. Following advanced discussions and after completing detailed due diligence with a potential partner, ImmuPharma has started the preparatory steps for Lupuzor’s™ pivotal phase III clinical…
ANNUAL GENERAL MEETING: 2014

Jun 27, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed. A summary of proxy votes is shown in the table below. Please also refer to the ‘Notice of Meeting’ in the Report & Accounts –…
ImmuPharma to access pioneering research in the Bordeaux region of France

Jun 27, 2014

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is delighted to provide further details on its activities in the Bordeaux region of France, working closely with one of its key collaborators at the CNRS*, ImmuPharma’s longstanding research partner, accessing novel drug research in the area of peptides. One key…

2026 (11)

2025 (24)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

A prodrug is a pharmacologically inactive or much less active compound that is converted inside the body (usually by metabolic enzymes) into the active drug that actually produces the therapeutic effect.

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MD, LLM

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 38 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr. Mauran-Ambrosino obtained her PhD in Chemistry from the Université de Bordeaux as a CIFRE fellow under the co-supervision of Dr. Goudreau. She then conducted postdoctoral research in cell biology at the Centre Hospitalier Universitaire (CHU) Pellegrin in Bordeaux.

In 2018, she joined Ureka, where she established both the Biology and Analytical Chemistry departments. In 2021, she became Chief Scientific Officer of Ureka Pharma. Since 2025, Dr. Mauran-Ambrosino has served as Head of R&D of the ImmuPharma Group.

Dr. Mauran-Ambrosino was a key contributor to the development of several programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr. Sébastien Goudreau obtained his PhD in Chemistry from the Université de Montréal as an NSERC fellow before conducting postdoctoral research at ETH Zürich as an FRQNT fellow. He later returned to Canada, where he co-founded FindMolecule Inc. and worked in the pharmaceutical industry.

Dr. Goudreau joined ImmuPharma in 2014 as Research Director and established the Ureka research laboratories in Bordeaux. Following the merger of ELRO and Ureka in 2019, he became Chief Scientific Officer of Ureka Pharma. In 2021, he was appointed Chief Executive Officer of ImmuPharma Biotech, and since 2025 he has served as Chief Scientific Officer of the ImmuPharma Group.

Dr. Goudreau and his team are credited with the discovery and development of several innovative programs, including BioAMB, BioCIN, the P140 companion diagnostic, and Kapiglucagon.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Lupuzor™ Phase III Pivotal Trial Update

Board Change

Tim McCarthy Appointed as Non-executive Chairman

Interim Results Announcement for the six months ended 30 June 2015

Richard Warr

ClinicalTrials.Gov registration of LUPUZOR™ Pivotal Phase III Trial

Term Sheet signed with US Investor to secure up to US$14 Million Funding For LUPUZOR™

Lupuzor’s Founder, Dr Slyviane Muller – Awarded Medal of Innovation from CNRS for Lupuzor™

ANNUAL GENERAL MEETING: 2015

Notice of Annual General Meeting: 29 May 2015

Preliminary Results Announcement for the year ended 31 December 2014

Dr Stéphane Méry Appointed as Non-Executive Director

Cancer Update: IPP-204106

Advance Assurance Received from H M Revenue and Customs Regarding “Enterprise Investment Scheme” Status

Landmark Collaboration Agreement & Commencement of Pivotal Phase III Lupuzor™ Study with Simbec-Orion

ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France

AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress

INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014

Lupuzor™ Gears Up To Start Pivotal Phase III trials

ANNUAL GENERAL MEETING: 2014

ImmuPharma to access pioneering research in the Bordeaux region of France